907190-73-2

Upstream product

• 920-39-8 isopropylmagnesium bromide 
• 127793-62-8 4-((tert-butyldiphenylsilyl)oxy)butanal 
• 130372-07-5 4-(tret-butyldiphenylsilyloxy)butan-1-ol 

Downstream Products

• 907190-74-3 4-{[tert-butyl(diphenyl)silyl]oxy}-1-isopropylbutyl-4-methylbenzenesulfonate 
• 907190-80-1 N-(4-{[tert-butyl(diphenyl)silyl]oxy}-1-isopropylbutyl)-3-{[3-(3,5-dichlorophenyl)-1-(2-naphthyl)-1H-pyrazol-5-yl]oxy}propanamide 
• 907190-81-2 3-{[3-(3,5-dichlorophenyl)-1-(2-naphthyl)-1H-pyrazol-5-yl]oxy}-N-(4-hydroxy-1-isopropylbutyl)propanamide 
• 907190-76-5 4-{[tert-butyl(diphenyl)silyl]oxy}-1-(isopropylbutyl)amine 
• 907190-75-4 [(4-azido-5-methylhexyl)oxy](tert-butyl)diphenylsilane 

Relevant academic research and scientific papers

Diaryl substituted pyrazoles as potent CCR2 receptor antagonists

We have identified and synthesized a series of diaryl substituted pyrazoles as potent antagonists of the chemokine receptor subtype 2. Structure-activity relationship studies directed toward improving the potency led to the discovery of 23 (IC50/sub

SUBSTITUTED PYRAZOLES AS MODULATORS OF CHEMOKINE RECEPTORS

Substituted pyrazole compounds such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including al

PYRIDIN-4-YLAMINE COMPOUNDS USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN

The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorde